Lavaca Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Lavaca Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-32	Closed	-$6K	–	348
2019 Q1	$6K	Hold	32	–	–	0.01%	309
2018 Q4	$5K	Buy	+32	New	+$5.54K	0.01%	294

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Lavaca Capital's VRTX Position: Q2 2019 in Review

Lavaca Capital sold out of Vertex Pharmaceuticals (VRTX) in Q2 2019, closing a stake of 32 shares — an estimated $6K sold.

Lavaca Capital first reported a position in VRTX in Q4 2018 and held it in 2 quarters. The position peaked at $6K in Q1 2019. 716 funds tracked by Wall St. Rank hold VRTX as of Q2 2019.

Lavaca Capital reported no remaining Vertex Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Lavaca Capital sold 32 Vertex Pharmaceuticals shares in Q2 2019, an estimated $6K.
Lavaca Capital first reported a position in Vertex Pharmaceuticals in Q4 2018 and held it in 2 quarters.
Lavaca Capital's Vertex Pharmaceuticals position peaked at $6K in Q1 2019.
716 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2019.

Based on Lavaca Capital's 13F filing for Q2 2019, filed 29 Jul 2019.